# DESCRIPTION

## TECHNICAL FIELD

- relate to biology and gene editing

## BACKGROUD

- introduce gene editing technology
- describe CRISPR-Cas9 technology
- highlight limitations of CRISPR-Cas9
- emphasize need for improving gene editing specificity

## SUMMARY OF THE INVENTION

- introduce compound for improving gene editing specificity
- define Formula I
- describe Z1
- describe W
- describe Z2
- describe Z3
- describe Z4
- describe A
- describe 5-8 membered ring
- describe preferred embodiments of 5-8 membered ring
- describe Formula A
- describe X
- describe R1, R2, and R3
- describe R4
- describe R5
- describe improving gene editing specificity
- describe inhibition of gene editing
- describe pharmaceutical composition
- describe 6-membered aromatic heterocyclic ring
- describe 4-6 membered unsaturated heterocyclic ring
- describe specific compounds
- describe gene editing methods
- describe base editing
- describe enzyme used for base editing
- describe gene editing applications
- describe sample targeted for gene editing

## DETAILED DESCRIPTION OF INVENTION

- introduce compound with structure as shown in Formula I to inhibit CRISPR/Cas9 protein function

### Terms

- define "improving gene editing specificity"
- define "C1-C3 alkylene"
- define "C3-C6 cycloalkylene"
- define "3-6 membered heterocyclylene"
- define "C6-C10 arylene"
- define "C3-C10 heteroarylene"
- define "C1-C10 alkyl"
- define "C2-C10 alkenyl"
- define "C2-C10 alkenyloxy"
- define "C2-C10 alkynyloxy"
- define "C2-C10 alkynyl"
- define "C1-C10 alkoxy"
- define "C3-C10 cycloalkyl"
- define "5-10 membered heterocyclic ring"
- define "3-10 membered carbocyclic ring"
- define "5-8 membered ring"
- define "halogen"
- define "gene editing inhibitors of the present invention"
- describe various groups in compound of Formula I
- describe pharmaceutically acceptable salt of compound of Formula A

### Example 1. Small Molecule Inhibitor Screening Based on EGFP Reporter

- describe EGFP reporter cell line construction and CRISPR/Cas9 recognition site insertion

### Example 2. The Activity of Compounds in Inhibiting the Cas9 on Endogenous Genes

- describe method of transfecting HEK293 cells with AAVS1-AS2 and pST-Cas9 plasmids
- describe result of gene modification rate with and without Compound 49
- describe result of gene modification rate with Compounds 115 and 48

### Example 3. Compound 49 Enhances the Specificity of SpyCas9-Based Gene Editing

- describe method of transfecting HEK293 cells with SpyCas9 and adding Compound 49

### Example 4. Inhibitory Activity of Compound 49 to Staphylococcus aureus Cas9 (SaCas9)

- describe method of transfecting cells with SaCas9 plasmid and adding Compound 49

### Example 5. The Inhibitory Activity of Compounds Modified on the Basis of Compound 49 on Gene Editing

- describe method of testing analogs of Compound 49 on gene editing

### Example 6. Compound 49 Regulates the Base Editing System

- describe method of transfecting HEK293T cells with sgRNA expression plasmid and dCas9-DNMT3a-DNMT
- describe result of deep sequencing showing Compound 49 reduces on-target cleavage

### Example 7. Improvement of Base Editing Specificity by Compound 49

- describe result of deep sequencing showing Compound 49 improves base editing specificity

### Example 8. Base Indel Editing of Compound 49

- describe result of deep sequencing showing Compound 49 inhibits indel of base editing

